Xiang lab - new review article in Int J Mol Sci
Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy
Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy
Luminal A breast cancer resistance mechanisms and emerging treatments, in “Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance”.
Invited editors of Book Series for Elsevier Publications.
The CINs of Polo-Like Kinase 1 in Cancer
Bibliometric analysis of personalized humanized mouse and Drosophila models for effective combinational therapy in cancer patients
Identification of therapeutically relevant targets in telomerase overexpressing prostate cancers
Humanized yeast genetic interaction mapping predicts synthetic lethal interactions of FBXW7 in breast cancer
SARS-CoV2 therapeutic discovery through genetic screens and repurposing drugs that target essential virus-host interactions
Riley Plett (Anderson lab) passed her MSc defence on May 4, 2020. Her thesis is titled: "New therapies for CREB3L1-deficient triple negative breast cancer".
Aptamers, the Nucleic Acid Antibodies, in Cancer Therapy
The Marathon of Hope Cancer Centres Network is a bold vision led by The Terry Fox Research Institute and The Terry Fox Foundation with support from dozens of research and funding partners across Canada. Its goal is to accelerate the adoption of Precision Medicine for cancer through the creation of a pan-Canadian network of designated cancer centres. This network represents a powerful collaborative platform that will embed research in the cancer clinic, uniting the top-tier cancer researchers and clinicians in Canada and allowing them to share their data and apply exciting new technologies such as artificial intelligence to deliver the best outcomes for each cancer patient in Canada, no matter where they are. Just as Terry Fox united Canada with his dream and determination, the Marathon of Hope Cancer Centres will unite this country by sharing knowledge, harnessing technology and working together towards finding cures for cancer. The Prairie Cancer Research Consortium, consisting of Alberta, Saskatchewan and Manitoba has launched its 2-year pilot project. The Saskatchewan participants include: Cancer Cluster members (Anderson, Vizeacoumar and Wu) as well as Andrew Freywald (Pathology) and Lynn Dwernychuk (Saskatchewan Cancer Agency).
New drugs to treat metastatic breast cancer
Targeting MAD1L1 overexpressing breast cancers
Manisha Yadav (Wu lab) passed her MSc defence on Mar 26, 2020. Her thesis is titled: "Structure and function of KH domain in DDX43 and DDX53 cancer antigen helicases".
Chelsea Cunningham (Vizeacoumar lab) passed her PhD defence on Mar 24, 2020. Her thesis is titled: "Synthetic dosage lethal interactions of Polo-like Kinase 1 and their application in cancer therapeutics".